Tirofiban Improves Outcomes for Strokes With No Other Tx Options
(MedPage Today) -- DALLAS -- Tirofiban (Aggrastat) improved acute ischemic stroke outcomes for patients who weren't candidates for thrombolytic or endovascular treatment, according to a phase III trial from China.
The glycoprotein IIb/IIIa inhibitor...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | China Health | Heart | Ischemic Stroke | Stroke | Thrombosis